Last updated: July 31, 2026
Metyrosine is a mature, low-volume catecholamine-synthesis inhibitor with no meaningful late-stage development program, no biosimilar exposure, and limited generic competition because the market is defined by a rare indication and specialist prescribing. Its commercial outlook depends more on uninterrupted supply, hospital access, and pheochromocytoma incidence than on clinical-trial expansion. The original U.S. exclusivity period has expired, and publicly available FDA materials do not indicate an active patent barrier protecting the product.
Metyrosine Clinical Trials, Market Analysis, Patent Status and Forecast
Metyrosine, sold in the United States as Demser and available in generic form, is the active ingredient alpha-methyl-L-tyrosine. It inhibits tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis. The drug reduces production of dopamine, norepinephrine and epinephrine.
The FDA approved metyrosine for short-term treatment of patients with pheochromocytoma to reduce catecholamine production, including before surgery and in patients with metastatic or unresectable disease. It is not a general antihypertensive and is used in a narrow specialist setting. [1]
What is metyrosine approved to treat?
Metyrosine is approved for the short-term management of patients with pheochromocytoma, a catecholamine-producing tumor arising from chromaffin cells.
FDA-approved uses
| Item |
Status |
| Active ingredient |
Metyrosine |
| Chemical name |
Alpha-methyl-L-tyrosine |
| Primary indication |
Pheochromocytoma |
| FDA dosage form |
250 mg oral capsules |
| Primary use |
Preoperative catecholamine reduction and control of catecholamine excess |
| U.S. reference product |
Demser |
| Regulatory category |
Small-molecule drug |
| Biosimilar pathway |
Not applicable |
| Main prescribers |
Endocrinologists, oncologists, surgeons and specialty hospitals |
The product is generally used with other blood-pressure and heart-rate control measures. The label identifies sedation, fatigue, extrapyramidal symptoms, crystalluria and crystalluria-related renal complications as important safety considerations. Patients must maintain adequate fluid intake. [1]
What clinical trials are evaluating metyrosine?
Metyrosine has no established broad-based Phase 2 or Phase 3 development program comparable to newer oncology or endocrine drugs. Clinical use is supported mainly by its pharmacology, historical clinical experience and studies in rare catecholamine-producing tumors.
Current clinical-development profile
Public trial registries and published literature characterize metyrosine research as:
- Small, specialist-led studies.
- Studies involving pheochromocytoma or paraganglioma.
- Pharmacologic investigations of catecholamine suppression.
- Perioperative management research.
- Case reports and retrospective series involving metastatic disease.
- Occasional use in complex neuroendocrine tumor protocols.
The drug’s clinical role is established, but the addressable patient population is small. This limits the commercial rationale for large randomized trials. ClinicalTrials.gov remains the principal U.S. registry for identifying newly posted studies involving metyrosine and pheochromocytoma. [2]
Clinical evidence relevant to commercial demand
Metyrosine’s demand is supported by four clinical factors:
- Pheochromocytoma and paraganglioma are rare tumors.
- A subset of patients has severe catecholamine excess requiring medical control.
- Surgery is often the preferred definitive treatment for localized disease.
- Metastatic or unresectable disease creates a smaller, chronic-use population.
Metyrosine is therefore an adjunctive and specialist therapy rather than a high-volume chronic medicine. Its use is concentrated in tertiary centers with expertise in endocrine hypertension and neuroendocrine tumors.
When does metyrosine lose market exclusivity?
Metyrosine lost its original small-molecule regulatory exclusivity decades ago. The drug was approved in 1979, and any original patent protection associated with the product would have expired long before the current market. [3]
U.S. exclusivity timeline
| Milestone |
Approximate timing |
| FDA approval of Demser |
1979 |
| Original small-molecule exclusivity |
Expired |
| Expected original patent protection |
Expired |
| Generic availability |
Established |
| Current market position |
Mature, low-volume prescription drug |
The product does not have a biologic reference-product period, pediatric exclusivity profile or modern New Chemical Entity exclusivity period that would delay generic entry today.
What is the Orange Book status of metyrosine?
Metyrosine is a small-molecule prescription drug, and its relevant U.S. regulatory information is reported through FDA drug listings and the Orange Book. Publicly available FDA materials do not indicate a current, commercially significant patent estate that blocks generic competition for metyrosine. [4]
Orange Book and patent position
| Patent issue |
Assessment |
| Active composition patent |
No meaningful current barrier identified |
| Active formulation patent |
No meaningful current barrier identified |
| Method-of-use patent |
No meaningful current barrier identified |
| Patent-term extension |
Not commercially relevant |
| Paragraph IV exposure |
Low, because the product is mature and generic |
| Regulatory exclusivity |
Expired |
| Generic substitution |
Legally available where an approved generic is stocked |
The absence of a patent barrier does not guarantee broad generic supply. In rare-disease markets, manufacturers may avoid products with low annual volume, limited pharmacy distribution and complex inventory requirements.
What patents protect metyrosine?
The commercially important protection for metyrosine is not an active patent portfolio. Its current protection profile is defined by historical approval, know-how and supply economics rather than enforceable exclusivity.
Formulation patents
Metyrosine is marketed as an oral capsule with a relatively simple dosage form. Publicly available FDA labeling does not identify a differentiated extended-release system, depot formulation, transdermal product or complex delivery platform. There is no clear commercial indication that a formulation patent materially restricts generic competition. [1]
Method-of-use patents
Metyrosine’s principal use, catecholamine suppression in pheochromocytoma, is the same therapeutic role reflected in the FDA label. Any historical use claims would be expected to have expired given the age of the product.
Potential future method-of-use claims could theoretically target:
- Specific metastatic pheochromocytoma populations.
- Combination therapy with radioligand treatment.
- Perioperative dosing protocols.
- Biomarker-defined catecholamine excess.
- Use in selected paraganglioma subgroups.
No such current patent strategy is publicly established as a major commercial barrier.
Manufacturing and process protection
Metyrosine is a defined small molecule rather than a biologic. Manufacturing risk is therefore lower than for monoclonal antibodies, cell therapies or peptide injectables. Potential barriers include:
- Active pharmaceutical ingredient qualification.
- Impurity control.
- Capsule-content uniformity.
- Stability and packaging requirements.
- Low-volume production economics.
- Regulatory maintenance of an approved supplier network.
These are operational barriers, not substitutes for patent exclusivity.
How many companies manufacture or market metyrosine?
The market has historically included the Demser reference product and generic suppliers. The number of active suppliers can change because manufacturers may discontinue low-volume products or sell rights to specialty distributors.
Competitive structure
| Competitive factor |
Market effect |
| Reference product |
Preserves brand recognition and clinical familiarity |
| Generic metyrosine |
Creates price competition |
| Limited indication |
Restricts market size |
| Specialist prescribing |
Concentrates demand |
| Low annual patient volume |
Raises supply-continuity risk |
| No biosimilar competition |
Not relevant because metyrosine is a small molecule |
| Hospital and specialty distribution |
Influences availability more than consumer demand |
Competition is likely to remain supply-led. A manufacturer with reliable inventory and established specialty-pharmacy distribution can retain commercial relevance even without patent protection.
What generic entry risks exist for metyrosine?
Generic entry has already occurred, so the primary risk is not future first entry. It is generic substitution, price erosion and supplier consolidation.
Generic launch scenarios
Base case
Generic metyrosine remains available through one or more suppliers. Pricing stays above that of high-volume generic capsules because production runs are small and distribution costs are high.
Downside case
One supplier exits, creating intermittent shortages or elevated acquisition costs. Hospitals and specialty pharmacies may rely on the reference product or emergency sourcing.
Upside case
A new generic supplier enters with dependable inventory and lower pricing. This improves access but compresses revenue for the brand and incumbent suppliers.
The small patient population limits the potential for severe price erosion seen in large primary-care markets. A manufacturer may have little incentive to compete aggressively if annual demand is too small to support several suppliers.
What is the market size for metyrosine?
Metyrosine is a niche orphan-market product. Public company filings generally do not disclose a separate revenue line for the drug, making a precise global market size difficult to establish from audited issuer data.
Market drivers
Demand is shaped by:
- Incidence of pheochromocytoma and paraganglioma.
- Number of patients receiving surgery.
- Prevalence of metastatic or unresectable disease.
- Treatment duration.
- Availability of alternative catecholamine-control therapies.
- Specialist-center prescribing.
- Product stocking by hospitals and specialty pharmacies.
- Frequency of supply interruptions.
The total treated population is small relative to mainstream endocrine drugs. Revenue can nevertheless be supported by specialty pricing, emergency use and the absence of a direct pharmacologic substitute with identical mechanism and indication.
Revenue exposure
Metyrosine is unlikely to represent material revenue exposure for a diversified pharmaceutical company. It can be commercially important for a small specialty-drug or rare-disease portfolio because a modest number of patients can generate concentrated product demand.
A useful commercial distinction is:
| Commercial characteristic |
Metyrosine |
| Patient volume |
Very low |
| Prescription concentration |
High among specialist centers |
| Price sensitivity |
Moderate, but constrained by limited supply |
| Patent-based pricing power |
Minimal |
| Clinical switching |
Limited where catecholamine suppression is required |
| Supply-chain importance |
High |
| Probability of blockbuster status |
Remote |
What is the projected metyrosine market through 2030?
A precise syndicated-market forecast is not publicly standardized. A scenario model is more appropriate than a single point estimate.
2025-2030 market scenarios
| Scenario |
Annual market direction |
Main assumptions |
| Low-growth |
Flat to low-single-digit growth |
Stable disease incidence, generic substitution and no major label expansion |
| Base case |
Low-single-digit growth |
Gradual diagnosis growth, stable specialist use and modest price increases |
| High case |
Mid-single-digit growth |
Greater recognition of metastatic disease, improved referral to specialty centers and sustained specialty pricing |
The market is unlikely to expand through mass adoption. Growth would more likely come from improved diagnosis, longer treatment in unresectable disease, broader use in specialized perioperative protocols and improved availability.
A reasonable investment view is that metyrosine offers defensive niche revenue rather than high-growth pharmaceutical exposure. The strongest commercial assets are regulatory continuity, manufacturing reliability and access to specialist channels.
How does metyrosine compare with competing treatments?
Metyrosine competes indirectly with alpha-adrenergic blockade, beta-blockade, calcium-channel blockade and treatment of the underlying tumor. These therapies do not all perform the same function.
| Treatment |
Primary role |
Relationship to metyrosine |
| Metyrosine |
Reduces catecholamine synthesis |
Direct pharmacologic control of production |
| Phenoxybenzamine |
Alpha-adrenergic blockade |
Controls receptor effects, not synthesis |
| Doxazosin |
Selective alpha blockade |
Alternative or complementary blood-pressure control |
| Beta blockers |
Heart-rate control |
Typically used only after alpha blockade |
| Calcium-channel blockers |
Blood-pressure control |
Alternative or adjunctive therapy |
| Surgery |
Definitive treatment for suitable tumors |
Reduces need for chronic drug therapy |
| Radioligand therapy |
Treatment for selected advanced tumors |
May reduce tumor burden but does not replace acute catecholamine control |
Metyrosine’s differentiating value is mechanism. It suppresses catecholamine production, while most alternatives block downstream physiologic effects.
What is the regulatory status of metyrosine outside the United States?
Regulatory status varies by jurisdiction, product holder and local marketing authorization. The United States remains the clearest reference market because FDA labeling and generic-drug records provide the most accessible regulatory framework.
International access may depend on:
- National approval of metyrosine.
- Named-patient or compassionate-use mechanisms.
- Hospital importation.
- Specialty distributors.
- Local recognition of pheochromocytoma treatment protocols.
The lack of a large multinational commercial program can make availability less consistent outside major endocrine and oncology markets.
What litigation affects metyrosine?
There is no widely recognized, commercially material patent litigation campaign centered on metyrosine comparable to litigation involving major branded oncology, diabetes or immunology products.
Litigation and settlement assessment
| Issue |
Current commercial significance |
| Paragraph IV litigation |
Limited |
| Patent-infringement campaign |
No major public campaign identified |
| Formulation litigation |
No material public dispute identified |
| Settlement agreements |
No major market-shaping settlement identified |
| REMS-related litigation |
Not a central issue |
| Antitrust exposure |
Low relative to high-revenue branded drugs |
The main legal risks are more likely to involve product quality, supply contracts, regulatory compliance or labeling than patent enforcement.
How strong is the patent estate for metyrosine?
The patent estate is weak from a current exclusivity perspective. Metyrosine has a long-established mechanism, a conventional oral dosage form and a mature indication. Its market position does not depend on blocking generic entry.
Patent-strength scorecard
| Category |
Strength |
| Composition-of-matter protection |
Expired |
| Core indication protection |
Expired or commercially immaterial |
| Formulation protection |
Limited |
| Delivery-system protection |
Limited |
| Manufacturing patents |
Not a major market barrier |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Low |
| Commercial defensibility |
Moderate only through supply and distribution |
A new patent strategy would require a differentiated product, such as a sustained-release formulation, a new combination regimen or a biomarker-selected use. Any such strategy would need clinical data and regulatory support to create meaningful value.
Key Takeaways
- Metyrosine is an FDA-approved oral inhibitor of catecholamine synthesis for pheochromocytoma.
- Its clinical use is concentrated in rare-disease and tertiary-care settings.
- No major late-stage clinical-trial expansion program is established.
- U.S. regulatory exclusivity and original patent protection have expired.
- The product has no biosimilar risk because it is a small molecule.
- Generic competition is established, but supplier availability remains commercially important.
- The market is expected to remain small, with flat to low-single-digit annual growth in the base case.
- Revenue exposure is more relevant to specialty-drug companies than to diversified pharmaceutical manufacturers.
- The strongest competitive defenses are reliable supply, specialist distribution and regulatory continuity.
- Patent litigation, Paragraph IV challenges and settlement agreements have limited apparent market impact.
FAQs
Is metyrosine a generic drug?
Yes. Metyrosine is available as the generic equivalent of Demser in the United States, subject to current supplier and distribution availability.
Can metyrosine replace phenoxybenzamine?
No. Metyrosine reduces catecholamine synthesis, while phenoxybenzamine blocks alpha-adrenergic receptors. Physicians may use them together or select therapy based on the patient’s tumor, blood pressure, surgery plan and tolerability.
Is metyrosine used for neuroblastoma?
Metyrosine is not broadly FDA-approved for neuroblastoma. It may appear in specialist research or off-label treatment strategies involving catecholamine-producing tumors, but its established U.S. indication is pheochromocytoma.
Does metyrosine have orphan-drug exclusivity today?
No current orphan-drug exclusivity period materially protects the mature product. Any original exclusivity associated with its historical approval has expired.
What could increase the metyrosine market?
The most plausible growth factors are higher diagnosis rates for pheochromocytoma and paraganglioma, increased treatment of metastatic disease, wider use at referral centers and improved product availability. A new formulation or approved combination regimen could expand value, but no such commercial program is established.
References
- U.S. Food and Drug Administration. (2017). Demser (metyrosine) capsules prescribing information.
- National Library of Medicine. (n.d.). ClinicalTrials.gov: Metyrosine and pheochromocytoma search records.
- U.S. Food and Drug Administration. (1979). FDA approval history and labeling for Demser (metyrosine).
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- National Cancer Institute. (n.d.). Pheochromocytoma and paraganglioma treatment information. Physician Data Query.
